- Tumors1000+
- Cancer937
- Pathology743
- Pathologic Processes723
- Immune System Diseases579
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer937
- Pathology743
- Pathologic Processes723
- Immune System Diseases579
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- PR positive
- ER negative
- PD-L1 negative
- PR negative
- EGFR positive
- EGFR negative
- ALK negative
- BRCA1 positive
- BRCA2 positive
- BRAF positive
- KRAS positive
- ALK positive
- CD20 positive
- p16 positive
- ROS1 negative
- BRAF negative
- MYC positive
- MET positive
- CD19 positive
- PIK3CA positive
- ROS1 positive
- HLA positive
- HR positive
- p16 negative
- HLA-A positive
- IDH positive
- RET positive
- HLA negative
- TP53 positive
- BCL2 positive
- BCL6 positive
- BRCA positive
- CCND1 positive
- CD5 positive
- Ex19del positive
- HBsAg positive
- L858R positive
- MET negative
- PALB2 positive
- BCR-ABL1 positive
- HPV positive
- IDH negative
- Philadelphia chromosome positive
- RET negative
- TP53 negative
- Anti-dsDNA positive
- BRCA1 negative
- HLA-A negative
- HPV negative
- PTEN positive
- RAS positive
- RB1 positive
- TTR positive
- ANA positive
- ATM positive
- BRCA2 negative
- CD30 positive
- FGFR2 positive
- MMR positive
- NTRK negative
- NTRK positive
- PTEN negative
- Philadelphia chromosome negative
- RB1 negative
- T790M positive
- TROP2 negative
- TROP2 positive
- ctDNA positive
- dMMR positive
- t(11;14) positive
- APP positive
- C5 positive
- CD19 negative
- CD19CAR positive
- CD20 negative
- CD23 positive
- CD4 positive
- CFTR positive
- CLDN18.2 positive
- COL7A1 positive
- EBV positive
- FGFR3 positive
- FLT3 negative
- FLT3 positive
- FMR1 positive
- H3 K27M positive
- HBB positive
- HbSS positive
- JAK2 positive
- KRAS negative
- MDM2 positive
- NF1 positive
- NF2 positive
- NRAS negative
- NRAS positive
- PD-1 positive
- PSEN1 positive
- PSEN2 positive
- RF positive
- SMN1 positive
- SPINK5 positive
- p53 positive
- β-thalassemia positive
- 11q negative
- 11q positive
- 19q negative
- 1p negative
- ABCA4 positive
- AKT positive
- ALPL positive
- Anti-Smith positive
- ApoE ε4 positive
- Aβ1-42 positive
- BCR/ABL positive
- CCND2 positive
- CCND3 positive
- CCNE1 positive
- CD30 negative
- CDK4 positive
- COL1A1 positive
- COL1A2 positive
- DICER1 positive
- DMD positive
- EPCAM positive
- ER or PR positive
- ER/PR positive
- EZH2 positive
- FGFR positive
- FKRP positive
- FOXO1 fusion negative
- FVIII positive
- G719X positive
- GLA positive
- HPV16 positive
- HRD positive
- HbE positive
- IAA positive
- IGHV negative
- IGHV positive
- KIT positive
- L861Q positive
- MGMT negative
- MLH1 positive
- MMR negative
- MSH2 positive
- MSH6 positive
- MSI-H negative
- MSI-H positive
- MSS positive
- MYC negative
- NTRK1 positive
- PD-1 negative
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- PKLR positive
- PMM2 positive
- PMS2 positive
- PTCH1 positive
- PiZZ positive
- RAS negative
- RPE65 positive
- S768I positive
- TMB positive
- TTR negative
- ZnT8 positive
- anti-AChR positive
- anti-MuSK positive
- anti-Ro autoantibodies positive
- anti-Ro/SSA positive
- anti-Sm positive
- core antibody positive
- dMMR negative
- del(17p) negative
- del(17p) positive
- hepatitis B DNA negative
- kappa light chain positive
- lambda light chain positive
- other sickle cell syndrome variants positive
- surface antigen positive
- t(11;14) negative
- (null)(null) positive
- +8 positive
- \-13 negative
- \-13 positive
- \-13/del(13q) positive
- \-17/add(17p) or del(17p) positive
- \-17/add(17p) positive
- \-5q negative
- \-5q positive
- \-7 positive
- \-7/del(7q) positive
- 11q aberration positive
- 11q del negative
- 11q del positive
- 11q23 abnormalities positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- 68Ga-DOTATATE PET/CT Scan
- ALK TKI Therapy
- Activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
- Acyclovir
- Adjuvant Radiation for 4-6 weeks
- Adjuvant Therapy (except reconstruction)
- Adjuvant or Neoadjuvant Chemotherapy with Metastatic Disease Development within 6 Months
- Allogeneic Stem Cell Transplant
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
3979 trials
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to see if bitopertin is effective and safe in treating EPP or XLP in participants aged 12 and above. It will investigate whether bitopertin can increase pain
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to compare the effects of different types of fluids given during surgery on acid-base balance and electrolytes in young patients. Patients will be randomly assigned to receive either normal saline or hypertonic saline
Efficacy & Safety Awards
No Placebo-Only Group
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial aims to test a combination of interventions, including improving sleep, cognitive exercises, and extended pain relief after heart surgery to reduce confusion, agitation, and decline in cognitive function. These interventions are based
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial will test a new long-acting HIV treatment for people who still have detectable virus levels despite taking oral medication. The study will look at how well the treatment works, how safe it is
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether giving azithromycin along with standard antibiotics to 8,000 women having a cesarean delivery can help reduce infections after childbirth. The study will compare the rates of
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial will randomly assign participants to receive either Luminopia dichoptic treatment, Vivid Vision dichoptic treatment, or continued optical correction alone. Participants will be assessed at 9 and 18 weeks
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares two types of radiation therapy for treating cancer that has spread to the brain. One type, called fractionated stereotactic radiosurgery (FSRS), delivers a high dose of radiation over
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
Summary"This trial aims to see if barzolvolimab is effective, safe, and well-tolerated in adults with Chronic Spontaneous Urticaria who have not responded well to common
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial is comparing the effects of combining immunotherapy (pembrolizumab) with chemotherapy (doxorubicin) versus using chemotherapy alone to treat patients with undifferentiated pleomorphic sar
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Get notified when new Lazy Eye trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to compare two treatments for children aged 4 to 7 with lazy eye. One treatment involves watching special movies with a headset for 1 hour per day, 6 days a week
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test if plozasiran injection is safe and effective in adults with high triglyceride levels. Participants will receive either plozasiran or a placebo every 3 months for a
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
Summary"This trial will test a new injection called plozasiran in adults with very high levels of triglycerides. Participants will receive either plozasiran or a placebo every 3 months for a
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test the safety and effectiveness of plozasiran injection in adults with severe high levels of triglycerides. Participants will receive either plozasiran or a placebo every 3 months
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial compares two drugs, rituximab and mosunetuzumab, in treating patients with low tumor burden follicular lymphoma. Rituximab targets a protein found on B
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing the effectiveness of ZILRETTA in reducing pain in people with glenohumeral osteoarthritis when compared to a placebo. The secondary objectives include comparing the pain
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug called pelacarsen to see if it is effective and safe for Black/African American and Hispanic individuals with heart disease and high levels of Lp(a). Participants
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to compare the overall survival of patients with certain types of advanced soft tissue sarcomas who have already tried 2 standard treatments, including one with anthracycline, with a new
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial will investigate the impact of a single dose of SRP-9003 on beta-sarcoglycan gene expression in individuals with limb-girdle muscular dystrophy type 2E/R
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Idiopathic Pulmonary Fibrosis trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial is for people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis who have completed treatment with a medicine called BI 1015550 in a previous study. The goal is to see how
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if adding a monoclonal antibody called dinutuximab to standard treatments like chemotherapy and stem cell transplantation can help treat children with a type of cancer called high risk neuroblast
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
1
2
3
…50